Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with neuroendocrine (NE) differentiation. Therapeutic strategies that address these aggressive variant PCs are urgently need...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Rep
Autori principali: Nyquist, Michael D., Corella, Alexandra, Coleman, Ilsa, De Sarkar, Navonil, Kaipainen, Arja, Ha, Gavin, Gulati, Roman, Ang, Lisa, Chatterjee, Payel, Lucas, Jared, Pritchard, Colin, Risbridger, Gail, Isaacs, John, Montgomery, Bruce, Morrissey, Colm, Corey, Eva, Nelson, Peter S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7453577/
https://ncbi.nlm.nih.gov/pubmed/32460015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2020.107669
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi